NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

Original reporting
Published Nov 17, 2026, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NNVC
Bullish
medium confidence
Mentioned
$NNVC
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$NNVCBullishMed
01

Why it matters

The filing adds concrete development and regulatory milestones (Phase II enrollment start dates, DRC approval, trial-site readiness) while also updating financial constraints (cash balance and runway to Nov 16, 2027). This combination can drive sentiment but also increases financing/dilution risk awareness.

02

Market read

Traders get a near-term catalyst mix: new Phase II trial starts and regulatory approval for NV-387, alongside a disclosed funding runway that can affect financing expectations.

03

What to watch

The article emphasizes setup and dosing/tolerability rationale but provides no Phase II efficacy outcomes yet; traders may need to discount the news until enrollment milestones and early safety/response readouts.

Relevance 7/10Novelty 6/10Timing: after the Nov 16, 2026 10-Q filing, with trial-start details disclosed in the same update

Background

NanoViricides (NNVC) reports filing its Form 10-Q for the quarter ended Sep 30, 2026 and updates NV-387 development, including two separate Phase II trials for Ebola BDBV and Mpox, plus Measles orphan designations.

Company-level read

Ticker impact

$NNVCBullishMedium confidence
Context

NanoViricides filed its 10-Q and disclosed NV-387 entering two Phase II trials, plus DRC regulatory approval and Ebola/Mpox trial setup progress.

Expected impact

Likely upward bias as trial initiation and regulatory approval reduce development uncertainty, partially offset by funding/runway concerns.

Evidence & confidence

The article is a primary company filing plus specific trial-start and regulatory-approval updates, which are typically supportive for biotech sentiment. However, it also states insufficient funding to continue operations through Nov 16, 2027, which can cap upside and increase dilution/financing risk.

Market effects

Highlights ongoing demand for oral broad-spectrum antivirals and the market sensitivity to trial starts and cash runway in small-cap biotech.

No direct regional market catalyst beyond DRC trial operations and regulatory activity.

Ebola and Mpox trial focus ties to global public-health priorities, but the tradable impact is primarily company-specific.

Counterpoint

Trial initiation and regulatory approvals may not translate into near-term value without interim efficacy data, and the stated funding gap raises dilution risk that can overwhelm clinical optimism.

Key entities

  • NanoViricides, Inc.

    Issuer filing the quarterly report and advancing NV-387 into Phase II trials.

  • NV-387

    Broad-spectrum antiviral oral gummies entering Phase II trials for Ebola BDBV and Mpox, with Measles orphan designations.

  • ACOREP (DRC regulatory agency)

    Granted approval to conduct the Ebola BDBV clinical trial in early August 2026.

  • SEC Form 10-Q

    Quarterly report filed Nov 16, 2026 for the quarter ended Sep 30, 2026.

Related articles

$NNVCMedAI 8/10

NanoViricides, Inc. (NNVC) NV-387 Ebola Trial Seen Advancing to Phase IIB

NanoViricides, Inc. (NNVC) reported progress in its Phase IIA trial for NV-387 Oral Gummies Ebola in the DRC, targeting 20 patients with a 28-day survival endpoint. The trial is expected to advance to Phase IIB upon completion. The company aims to progress NV-387 across multiple indications, with a clearer catalyst expected upon IIA completion and IIB start.

$NNVCMedAI 8/10

NanoViricides Reports Positive Juvenile Safety Data for NV-387, But Going Concern Risk Persists

NanoViricides (NNVC) reported positive juvenile safety data for NV-387, its antiviral drug, in a 12-day mouse study. The drug was well-tolerated at all dose levels, with no adverse effects. The company plans to use these results to support pediatric clinical trials for Ebola, Mpox, and measles, subject to further development and regulatory approval. NV-387 is currently in Phase II trials for Ebola and Mpox.

$NNVCMedAI 8/10

A drug being tested for Ebola showed no harmful effects in a young-mouse safety study

NanoViricides, Inc. (NNVC) announced that its antiviral drug NV-387 showed strong safety and tolerability in a juvenile mouse study, paving the way for pediatric clinical trials. NV-387 is in Phase II trials for Ebola and Mpox, with potential pediatric cohorts if successful. The company also has plans for a Phase II trial for Measles, which has received Orphan Drug and Rare Pediatric Disease Designations from the FDA.